Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group
- 1 January 2010
- journal article
- research article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 55 (1) , 50-60
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Immunoregulatory role of TNFα in inflammatory kidney diseasesKidney International, 2009
- Successful Anti-TNFα Treatment in a Child with Posttransplant Recurrent Focal Segmental GlomerulosclerosisAmerican Journal of Transplantation, 2009
- Phase I Trial of Rosiglitazone in FSGSClinical Journal of the American Society of Nephrology, 2009
- Many cytokines are very useful therapeutic targets in diseaseJournal of Clinical Investigation, 2008
- Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: A systematic reviewArthritis Care & Research, 2008
- A tumor necrosis factor-α–mediated pathway promoting autosomal dominant polycystic kidney diseaseNature Medicine, 2008
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Renal macrophage activation and Th2 polarization precedes the development of nephrotic syndrome in Buffalo/Mna ratsKidney International, 2005
- Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritisNephrology Dialysis Transplantation, 2005